Insulatard

Insulin Human, the active ingredient in Insulatard, is an insulin presented as a suspension for injection for subcutaneous use. It provides basal insulin coverage to manage blood glucose in individuals with type 1 or type 2 diabetes mellitus.

GNH USA supplies Insulatard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Insulatard is used to provide basal insulin therapy in the management of diabetes mellitus.

- Type 1 diabetes mellitus: supplies long‑acting insulin to control fasting glucose and reduce hyperglycaemia. - Type 2 diabetes mellitus: adds basal insulin to supplement endogenous secretion and improve overall glycaemic control.

Insulatard may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Hypoglycaemia: low blood glucose episodes, especially if meals are missed or dosing is excessive. - Injection‑site pain or erythema: mild discomfort or redness at the injection site. - Lipodystrophy: localized thickening or loss of subcutaneous fat with repeated injections. - Weight gain: modest increase in body weight over time. - Edema: mild fluid retention, often in the lower extremities. - Allergic skin reaction: itching or rash at the site.

Serious or Rare Side Effects: - Severe hypoglycaemia: profound low glucose requiring assistance. - Anaphylactic reaction: life‑threatening systemic allergy with airway compromise. - Insulin antibodies: formation of antibodies that may alter insulin action. - Hypokalemia: low potassium levels secondary to rapid glucose shift.

When using Insulatard, several precautions should be observed to ensure safe and effective therapy.

- Dose titration: adjust the dose gradually based on self‑monitored blood glucose and clinical response. - Hypoglycaemia risk: educate patients to recognise and treat low glucose promptly. - Renal or hepatic impairment: monitor closely and consider dose reduction in severe dysfunction. - Pregnancy and lactation: use only if the potential benefit outweighs uncertain risk, as safety data are limited. - Concomitant medications: review other glucose‑lowering agents to avoid additive hypoglycaemic effect. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the suspension.

Insulatard can interact with other medicines, influencing glucose control or insulin action.

Major Interactions (Avoid): - Sulfonylureas or meglitinides: combined use markedly increases risk of severe hypoglycaemia. - Beta‑blockers: may mask typical hypoglycaemia symptoms such as tachycardia. - MAO‑inhibitors: rare reports of potentiated insulin effect leading to hypoglycaemia.

Moderate Interactions (Monitor Closely): - Oral hypoglycaemic agents (e.g., metformin, DPP‑4 inhibitors): additive glucose‑lowering effect may require dose adjustment. - Corticosteroids: can raise blood glucose, potentially necessitating higher insulin doses. - Thiazide diuretics: may cause modest hyperglycaemia, requiring closer monitoring.